SPONSOR
Hoffmann-La Roche
Total Trials
15
Recruiting
15
Phases
Phase 1, Phase 4, Phase 2, Phase 3, Phase 1, Phase 2, Phase 2, Phase 3
Conditions studied: Multiple MyelomaMetastatic Colorectal CancerMuscular Atrophy, SpinalLupusSystemic Lupus ErythematosusLupus NephritisHemophilia AALK Fusion-positive Solid or CNS TumorsNeoplasmsBreast Cancer
Hoffmann-La Roche is a clinical research sponsor with 15 registered studies on ClinicalTrials.gov, of which 15 are actively recruiting participants. Research covers conditions including Multiple Myeloma, Metastatic Colorectal Cancer, Muscular Atrophy, Spinal, Lupus.
The trial portfolio spans Phase 1, Phase 4, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Hoffmann-La Roche
How many clinical trials has Hoffmann-La Roche sponsored?
ClinicalMetric currently tracks 15 clinical trials sponsored by Hoffmann-La Roche, of which 15 are actively recruiting participants. These trials cover conditions including Multiple Myeloma, Metastatic Colorectal Cancer, Muscular Atrophy, Spinal. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Hoffmann-La Roche research focus on?
Hoffmann-La Roche clinical trials span Multiple Myeloma, Metastatic Colorectal Cancer, Muscular Atrophy, Spinal, Lupus, Systemic Lupus Erythematosus, and additional conditions. The research pipeline includes Phase 1, Phase 4, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Hoffmann-La Roche clinical trial?
To participate in a Hoffmann-La Roche trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Hoffmann-La Roche trials with current recruitment status updated daily.
Clinical Trials by Hoffmann-La Roche
NCT06934044 Phase 1
Recruiting
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
NCT04929223 Phase 1
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
NCT05861999 Phase 4
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Muscular Atrophy, Spinal
NCT07598396 Phase 2
Recruiting
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Lupus
NCT05039619 Phase 2
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Lupus Nephritis
NCT07416526 Phase 3
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Hemophilia A
NCT04774718 Phase 1, Phase 2
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
ALK Fusion-positive Solid or CNS Tumors
NCT06884618 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Neoplasms
NCT07226206 Phase 1, Phase 2
Recruiting
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Hemophilia A
NCT07054190 Phase 2
Recruiting
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Breast Cancer
NCT07284121
Recruiting
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
NCT05562947 Phase 3
Recruiting
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
NCT07555938 Phase 3
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Multiple Myeloma
NCT06819891 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
NCT07413939 Phase 2, Phase 3
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
HER2-positive Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology